Paradigm Biocapital Advisors LP

Position in ERAS — Erasca, Inc.

CIK 1855655 NEW YORK, NY

Position in ERAS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$174,956,000

+$6,802,082 QoQ

Shares Held

9,550,000

-8.1% QoQ

Ownership

2.73%

of shares outstanding

% of Portfolio

3.80%

of 13F equity value

Holder Rank

#10

of 257 holders

Holding Since

Jun 2024

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Paradigm Biocapital Advisors LP holds $4,608,890,546 across 28 Biotechnology names. ERAS ranks #9 (3.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	6,361,323	$1,191,348,571
2	EWTX	Edgewise Therapeutics, Inc.	10,215,455	$415,053,936
3	GMAB	Genmab A/S	13,133,131	$360,767,108
4	SYRE	Spyre Therapeutics, Inc.	3,840,778	$340,984,270
5	APGE	Apogee Therapeutics, Inc.	1,576,385	$209,233,581
6	ORKA	Oruka Therapeutics, Inc.	2,144,526	$204,094,539
7	TNGX	Tango Therapeutics, Inc.	6,357,523	$198,736,168
8	BLTE	Belite Bio, Inc	1,232,877	$189,844,564

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$174,956,000	9,550,000	-8.1%	Shares	Sole	2026-08-14
2026-03-31	$168,153,918	10,392,702	-26.6%	Shares	Sole	2026-05-15
2026-01-07	$78,372,521	15,159,095	—	Shares	Sole	2026-01-14
2025-12-31	$52,671,833	14,159,095	+4.4%	Shares	Sole	2026-02-17
2025-09-30	$29,560,837	13,560,017	+13.9%	Shares	Sole	2025-11-14
2025-06-30	$15,122,121	11,907,182	+10.2%	Shares	Sole	2025-08-14
2025-03-31	$14,799,224	10,802,354	+0.5%	Shares	Sole	2025-05-15
2024-12-31	$26,988,408	10,752,354	+0.8%	Shares	Sole	2025-02-14
2024-09-30	$29,124,024	10,668,141	+47.1%	Shares	Sole	2024-11-14
2024-06-30	$17,110,000	7,250,000	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.